H.C. Wainwright raised the firm’s price target on Xoma (XOMA) to $123 from $117 and keeps a Buy rating on the shares after the company acquired ...

H.C. Wainwright analyst Ram Selvaraju reiterated a Hold rating on Kezar Life Sciences (KZR – Research Report) today. The company’s shares ...

On Friday, Energy Fuels Inc (UUUU) stock saw a modest uptick, ending the day at $7.29 which represents a slight increase of $0.49 or 7.21% from the prior close of $6.8. The stock opened at $7.1 and ...

H.C. Wainwright lowered the firm’s price target on Splash Beverage (SBEV) to 50c from $1 and keeps a Buy rating on the shares ...

Shares of Novocure Ltd. skyrocketed over 55% on Monday afternoon, reaching levels last seen in August 2023, as the company ...

H.C. Wainwright has recently raised Syros Pharmaceuticals Inc (SYRS) stock to Buy rating, as announced on November 4, 2020, according to Finviz. Earlier, on September 22, 2020, Alliance Global ...

WARMINSTER, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage ...

The Company clarified that they are not obligated to sell any Shares under this agreement. H.C. Wainwright & Co., LLC will act to sell the Shares based on electroCore’s instructions and within the ...

H.C. Wainwright analyst Andrew Fein lowered the firm’s price target on Alector (ALEC) to $7 from $35 and keeps a Buy rating ...

H.C. Wainwright analyst Arthur He downgraded Poseida Therapeutics (PSTX) to Neutral from Buy with a price target of $9, down from $20, after Roche (RHHBY) agreed to acquire the company for $1.5B ...

H.C. Wainwright raised the firm’s price target on BridgeBio (BBIO) to $49 from $43 and keeps a Buy rating on the shares. Acoramidis received regulatory approval with the label underscoring ...

Phunware (NASDAQ:PHUN) shares retreated 11% in Tuesday late morning trading after H.C. Wainwright & Co. downgraded the application software company to Neutral from Buy, as analyst Scott Buck ...